Moxifloxacin and pyrazinamide susceptibility testing in a complex case of multidrug-resistant tuberculosis

Int J Tuberc Lung Dis. 2011 Mar;15(3):417-20.


Multidrug-resistant tuberculosis (MDR-TB) is a public health problem of global concern. It is critical that drug susceptibility testing (DST) methods accurately predict clinical response. We present a patient with a challenging case of MDR-TB with additional resistance to quinolones and pyrazinamide. Treatment with a regimen including high-dosage moxifloxacin, based on additional genotypic and phenotypic DST, produced excellent results. This case highlights the possibility of treatment with high-dose fluoroquinolones despite apparent bacterial resistance to these agents. Improved DST methods are necessary for both agents. Development of genotypic approaches may offer a susceptibility profile rapidly, enabling early introduction of individualised treatments.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antitubercular Agents / pharmacology*
  • Aza Compounds / pharmacology*
  • Drug Therapy, Combination
  • Fluoroquinolones
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Moxifloxacin
  • Pyrazinamide / pharmacology*
  • Quinolines / pharmacology*
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Tuberculosis, Multidrug-Resistant / microbiology


  • Antitubercular Agents
  • Aza Compounds
  • Fluoroquinolones
  • Quinolines
  • Pyrazinamide
  • Moxifloxacin